Recent progress of proteomics in nonalcoholic fatty liver disease

Progress in Biochemistry and Biophysics

Volumn 38, Issue 6, 2011, Pages 487-498

  Ye, Hua ^a,b   Liu, Wei ^b   Yu, Chao Hui ^a   Li, You Ming ^a   Jiang, Ying ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Biomarkers; Nonalcoholic fatty liver disease; Pathogenesis; Proteomics

Indexed keywords

EID: 79960263086     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2010.00566     Document Type: Article

References (37)

1. Chitturi S, Farrell G C, Hashimoto E, et al. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol, 2007, 22(6): 778-787 (Pubitemid 46915352)
2. Loria P, Adinolfi L E, Bellentani S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis, 2010, 42(4): 272-282
3. Tiniakos D G, Vos M B and Brunt E M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol, 2010, 5: 145-171
4. Fan J G and Farrell G C. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol, 2009, 50(1): 204-210
5. Gray J, Chattopadhyay D, Beale G S, et al. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer, 2009, 9: 271
6. Trak-Smayra V, Dargere D, Noun R, et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut, 2009, 58(6): 825-832
7. Ulukaya E, Yilmaz Y, Moshkovskii S, et al. Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Scand J Gastroenterol, 2009, 44(12): 1471-1476
8. Bell L N, Theodorakis J L, Vuppalanchi R, et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology, 2010, 51(1): 111-120
9. Rodriguez-Suarez E, Duce A M, Caballeria J, et al. Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl, 2010, 4(4): 362-371
10. Estep J M, Birerdinc A and Younossi Z. Non-invasive diagnostic tests for non-alcoholic fatty liver disease. Curr Mol Med, 2010, 10(2): 166-172
11. Younossi Z M, Baranova A, Stepanova M, et al. Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. J Proteome Res, 2010, 9(6): 3218-3224
12. Delles C, Schiffer E, von Zur Muhlen C, et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens, 2010, 28(11): 2316-2322
13. Nemirovskiy O, Li W W and Szekely-Klepser G. Design and validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide in human urine: application as a biomarker of osteoarthritis. Methods Mol Biol, 2010, 641: 253-270
14. Snow A, Gozal D, Valdes R, Jr., et al. Urinary proteins for the diagnosis of obstructive sleep apnea syndrome. Methods Mol Biol, 2010, 641: 223-241
15. Sinchaikul S, Tantipaiboonwong P, Sriyam S, et al. Different sample preparation and detection methods for normal and lung cancer urinary proteome analysis. Methods Mol Biol, 2010, 641: 65-88
16. Shi Q, Hong H, Senior J, et al. Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol, 2010, 4(2): 225-234
17. Charlton M, Viker K, Krishnan A, et al. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology, 2009, 49(4): 1375-1384
18. Zhang X, Yang J, Guo Y, et al. Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis. Hepatology, 2010, 51(4): 1190-1199
19. Van Greevenbroek M M, Vermeulen V M and De Bruin T W. Identification of novel molecular candidates for fatty liver in the hyperlipidemic mouse model, HcB19. J Lipid Res, 2004, 45(6): 1148-1154 (Pubitemid 38679511)
20. Wang H, Chan P K, Pan S Y, et al. ERp57 is up-regulated in free fatty acids-induced steatotic L-02 cells and human nonalcoholic fatty livers. J Cell Biochem, 2010, 110(6): 1447-1456
21. DiBello P M, Dayal S, Kaveti S, et al. The nutrigenetics of hyperhomocysteinemia: quantitative proteomics reveals differences in the methionine cycle enzymes of gene-induced versus diet-induced hyperhomocysteinemia. Mol Cell Proteomics, 2010, 9(3): 471-485
22. Santamaria E, Avila M A, Latasa M U, et al. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci U S A, 2003, 100(6): 3065-3070 (Pubitemid 36356540)
23. Singh A, Wirtz M, Parker N, et al. Leptin-mediated changes in hepatic mitochondrial metabolism, structure, and protein levels. Proc Natl Acad Sci U S A, 2009, 106(31): 13100-13105
24. Fiorentino L, Vivanti A, Cavalera M, et al. Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology, 2010, 51(1): 103-110
25. Douette P, Navet R, Gerkens P, et al. Steatosis-induced proteomic changes in liver mitochondria evidenced by two-dimensional differential in-gel electrophoresis. J Proteome Res, 2005, 4(6): 2024-2031 (Pubitemid 41814268)
26. Calvert V S, Collantes R, Elariny H, et al. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology, 2007, 46(1): 166-172 (Pubitemid 47171933)
27. de Sousa Abreu R, Penalva L O, Marcotte E M, et al. Global signatures of protein and mRNA expression levels. Mol Biosyst, 2009, 5(12): 1512-1526
28. Younossi Z M, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology, 2005, 42(3): 665-674 (Pubitemid 41233660)
29. Kirpich I A, Gobejishvili L N, Homme M B, et al. Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J Nutr Biochem, 2011, 22(1): 38-45
30. Gao B, Jeong W I and Tian Z. Liver: An organ with predominant innate immunity. Hepatology, 2008, 47(2): 729-736 (Pubitemid 351280741)
31. Day C P and James O F. Steatohepatitis: a tale of two "hits"? Gastroenterology, 1998, 114(4): 842-845
32. Meneses-Lorente G, Guest P C, Lawrence J, et al. A proteomic investigation of drug-induced steatosis in rat liver. Chem Res Toxicol, 2004, 17(5): 605-612 (Pubitemid 38669517)
33. Meneses-Lorente G, Watt A, Salim K, et al. Identification of early proteomic markers for hepatic steatosis. Chem Res Toxicol, 2006, 19(8): 986-998 (Pubitemid 44384829)
34. Bell L N, Lee L, Saxena R, et al. Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol, 2010, 298(5): G746-754
35. Lee L, Alloosh M, Saxena R, et al. Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology, 2009, 50(1): 56-67
36. Geiger T, Cox J, Ostasiewicz P, et al. Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat Methods, 2010, 7(5): 383-385
37. Song Y, Hao Y, Sun A, et al. Sample preparation project for the subcellular proteome of mouse liver. Proteomics, 2006, 6(19): 5269-5277 (Pubitemid 44547165)